Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RHEI Begins Final China Trial for Oral Cadidiasis Product

publication date: Dec 8, 2008

RHEI Pharmaceuticals has begun the final China clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system. Tibozole will attempt to approve its efficacy as a treatment for oral candidiasis, a condition that affects immuno-compromised patients with HIV/AIDS and cancer patients undergoing chemotherapy. RHEI, a venture-backed company, has offices in the US and Belgium, but its operations are in China. More details.

Stock Symbols: (NYSE: JNJ) (NSDQ: APPA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital